Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
Milestone Pharmaceuticals announced that CARDAMYST (etripamil) data and program updates will be presented at three upcoming cardiology conferences: CAPP National Conference (Oct 22-24), TCT 2026 (Oct 31-Nov 3), and AHA Scientific Sessions 2026 (Nov 6-9). Presentations span the approved PSVT indication plus the investigational AFib-RVR use, including the Phase 3 ReVeRA-301 trial design for atrial fibrillation with rapid ventricular rate.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.